Research programme: ubiquitin-proteasome inhibitors - Millennium/Roche
Alternative Names: Ubiquitin-proteasome inhibitors research programme - Millennium/RocheLatest Information Update: 31 May 2006
Price :
$50 *
At a glance
- Originator Millennium Pharmaceuticals; Roche
- Class
- Mechanism of Action Immunomodulators; Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cachexia
Most Recent Events
- 31 Dec 2005 No development reported - Preclinical for Cachexia in USA (unspecified route)
- 15 Dec 1997 Preclinical development for Cachexia in USA (Unknown route)